IL265917A - Combination of a pd-1 antagonist and eribulin for treating urothelial cancer - Google Patents
Combination of a pd-1 antagonist and eribulin for treating urothelial cancerInfo
- Publication number
- IL265917A IL265917A IL265917A IL26591719A IL265917A IL 265917 A IL265917 A IL 265917A IL 265917 A IL265917 A IL 265917A IL 26591719 A IL26591719 A IL 26591719A IL 265917 A IL265917 A IL 265917A
- Authority
- IL
- Israel
- Prior art keywords
- eribulin
- antagonist
- combination
- urothelial cancer
- treating urothelial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408328P | 2016-10-14 | 2016-10-14 | |
| PCT/US2017/056552 WO2018071792A1 (en) | 2016-10-14 | 2017-10-13 | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL265917A true IL265917A (en) | 2019-06-30 |
Family
ID=60388115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265917A IL265917A (en) | 2016-10-14 | 2019-04-08 | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190263927A1 (https=) |
| EP (1) | EP3525818A1 (https=) |
| JP (1) | JP2019530706A (https=) |
| KR (1) | KR20190082782A (https=) |
| CN (1) | CN110072552A (https=) |
| AU (1) | AU2017342462A1 (https=) |
| BR (1) | BR112019007145A2 (https=) |
| CA (1) | CA3040465A1 (https=) |
| IL (1) | IL265917A (https=) |
| MX (1) | MX2019003994A (https=) |
| SG (1) | SG11201902974PA (https=) |
| WO (1) | WO2018071792A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| JP2022547650A (ja) * | 2019-07-09 | 2022-11-15 | カディラ・ヘルスケア・リミテッド | ヒトプログラム細胞死受容体ｐｄ－１に対する抗体 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| SI4076385T1 (sl) * | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP4454151B2 (ja) | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| US9707302B2 (en) * | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CN117100753A (zh) * | 2015-02-12 | 2023-11-24 | 大连万春布林医药有限公司 | 普那布林联合免疫检查点抑制剂的用途 |
| AU2016226157B2 (en) * | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
-
2017
- 2017-10-13 WO PCT/US2017/056552 patent/WO2018071792A1/en not_active Ceased
- 2017-10-13 BR BR112019007145A patent/BR112019007145A2/pt not_active IP Right Cessation
- 2017-10-13 CA CA3040465A patent/CA3040465A1/en not_active Abandoned
- 2017-10-13 EP EP17800964.3A patent/EP3525818A1/en not_active Withdrawn
- 2017-10-13 SG SG11201902974PA patent/SG11201902974PA/en unknown
- 2017-10-13 KR KR1020197013370A patent/KR20190082782A/ko not_active Withdrawn
- 2017-10-13 CN CN201780077525.7A patent/CN110072552A/zh active Pending
- 2017-10-13 US US16/341,579 patent/US20190263927A1/en not_active Abandoned
- 2017-10-13 AU AU2017342462A patent/AU2017342462A1/en not_active Abandoned
- 2017-10-13 MX MX2019003994A patent/MX2019003994A/es unknown
- 2017-10-13 JP JP2019518975A patent/JP2019530706A/ja not_active Withdrawn
-
2019
- 2019-04-08 IL IL265917A patent/IL265917A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201902974PA (en) | 2019-05-30 |
| CA3040465A1 (en) | 2018-04-19 |
| WO2018071792A1 (en) | 2018-04-19 |
| US20190263927A1 (en) | 2019-08-29 |
| CN110072552A (zh) | 2019-07-30 |
| BR112019007145A2 (pt) | 2019-07-02 |
| MX2019003994A (es) | 2019-09-19 |
| EP3525818A1 (en) | 2019-08-21 |
| JP2019530706A (ja) | 2019-10-24 |
| AU2017342462A1 (en) | 2019-05-02 |
| KR20190082782A (ko) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254133B (en) | Combination of pd-1 antagonist and eribulin for cancer treatment | |
| IL265917A (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| IL246760A0 (en) | Combination of pd-1 antagonist and vegfr inhibitor for cancer treatment | |
| IL247102A0 (en) | Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment | |
| IL250187B (en) | A combination of a pd-1 antagonist and a listeria-based vaccine for the treatment of prostate cancer | |
| ZA201807766B (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
| IL260199B (en) | Cancer treatment methods | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anticancer agents | |
| WO2016154412A9 (en) | Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer | |
| IL262342A (en) | Cancer treatment methods | |
| SG11201802952TA (en) | Compounds for treatment of cancer and epigenetics | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| IL247808A (en) | History of splosporin for the treatment of cancer |